Latest Commercialisation Strategy News

AnteoTech Ltd reports strong quarterly progress with a key US joint development agreement, significant manufacturing scale-up, and expanded market access in South Korea, underpinning its 2025 commercialisation strategy.

Metallium Ltd has marked a pivotal quarter with a U.S. Department of Defense contract award, strategic partnerships, and progress on its Texas Flash Joule Heating plant, positioning itself as a key player in the U.S. critical metals recovery sector.

Element 25 has appointed Altris Engineering to lead the AU$64.8 million expansion of its Butcherbird manganese mine, a move that underpins its strategy to supply high-purity battery materials to the US electric vehicle market.

BCAL Diagnostics has launched a $10 million convertible note facility, with $5 million already committed, to strengthen its capital position and accelerate commercialisation of its cancer detection technologies.

BCAL Diagnostics has established a $10 million convertible note facility, with $5 million already committed, to accelerate its cancer detection technologies and commercial milestones.

Hazer Group has received a $4.58 million R&D tax incentive refund for FY25, reinforcing its financial position as it advances its methane pyrolysis technology towards commercialisation.

ClearVue Technologies has raised A$4.6 million in a strongly supported placement to accelerate international certification and ongoing innovation of its solar façade products.

Mammoth Minerals has initiated its first-ever diamond drilling campaign at the Excelsior Gold-Silver Project in Nevada, aiming to unlock detailed geological insights and advance metallurgical testing. Meanwhile, the company has deferred payment terms on its Skyline Copper Project in Canada as it sharpens focus on US gold assets.

Papyrus Australia has appointed Daniel Schmidt as CEO and secured a $250k government grant alongside a binding agreement to produce biodegradable mining products, marking a decisive shift from R&D to commercial operations.

Orthocell has appointed its first Canadian distributor for Remplir, its innovative nerve repair device, ahead of an official launch at a major surgical conference in Vancouver. The move marks a significant step in expanding the product’s international footprint.

INOVIQ Limited has obtained exclusive worldwide rights to novel ovarian cancer biomarker IP from UniQuest, propelling its EXO-OC™ test closer to commercial launch. The test’s exceptional sensitivity and specificity position it as a potential breakthrough in early cancer detection.

Memphasys Limited is intensifying its commercial push for Felix, an innovative automated sperm separation system for IVF, backed by a landmark Middle East partnership and a fresh capital raise to scale manufacturing and sales.